DefinePK

Abstract

Background and Objectives Breast cancer is one of the most common cause of cancer death worldwide. Tumor markers have been widely used for assessing the treatment response and early diagnosis of recurrence. The present work was designed to evaluate the new off label use of doxycycline alongside with the ordinary cyclophosphamide medication in combination with the systemic adjuvant treatment protocol in early breast cancer females. Materials and Methods Estrogen ER, B-cell lymphoma-2 Bcl-2 and epidermal growth factor EGF were estimated. Early diagnostic breast cancer patients treated with adjuvant protocol were additionally orally administered with a dose of 100 mg doxycycline or 600 mg m1502 cyclophosphamide and repeat every 3 weeks for 4 cycles. Results The results revealed significant increase in ER, Bcl-2 and EGF levels in serum of breast cancer patients as compared with normal females. Treatments with doxycycline or cyclophosphamide in combination with the adjuvant treatment regimens improved all the measured parameters with variable degrees. Conclusion Doxycycline alongside the adjuvant treatment protocol recorded the most potent effect in ameliorating ER, Bcl-2 and EGF levels.